Patents by Inventor Takazumi Taniguchi
Takazumi Taniguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12201602Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.Type: GrantFiled: August 15, 2022Date of Patent: January 21, 2025Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yasuko Yamamoto, Takazumi Taniguchi
-
Publication number: 20230285411Abstract: The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.Type: ApplicationFiled: August 12, 2021Publication date: September 14, 2023Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yasuko YAMAMOTO, Takazumi TANIGUCHI, Atsushi SHIMAZAKI, Erika KIMURA
-
Publication number: 20220387372Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.Type: ApplicationFiled: August 15, 2022Publication date: December 8, 2022Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yasuko YAMAMOTO, Takazumi TANIGUCHI
-
Patent number: 11446273Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.Type: GrantFiled: December 20, 2018Date of Patent: September 20, 2022Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yasuko Yamamoto, Takazumi Taniguchi
-
Publication number: 20210106569Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining omidenepag and ripasudil or netarsudil, each complement and/or enhances the intraocular pressure lowering effect. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.Type: ApplicationFiled: December 20, 2018Publication date: April 15, 2021Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Masahiro FUWA, Takazumi TANIGUCHI
-
Patent number: 10940144Abstract: The present invention aims to find a novel pharmaceutical use of omidenepag, esters thereof, or salts thereof. The present inventors have made intensive studies to find a novel pharmaceutical use of omidenepag, an ester thereof, or a salt thereof, and have found as a result that omidenepag, an ester thereof, or a salt thereof significantly dilates retinal blood vessels, and significantly increases blood flow. Therefore, omidenepag, an ester thereof, or a salt thereof is expected to protect retinal nerve cells and be useful for prevention and/or treatment of ophthalmic diseases involving retinal nerve cell disorder.Type: GrantFiled: September 27, 2018Date of Patent: March 9, 2021Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Takazumi Taniguchi, Takahiro Akaishi, Hitoshi Nakazawa
-
Publication number: 20200316009Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.Type: ApplicationFiled: December 20, 2018Publication date: October 8, 2020Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yasuko YAMAMOTO, Takazumi TANIGUCHI
-
Publication number: 20200188377Abstract: The present invention aims to find a novel pharmaceutical use of omidenepag, esters thereof, or salts thereof. The present inventors have made intensive studies to find a novel pharmaceutical use of omidenepag, an ester thereof, or a salt thereof, and have found as a result that omidenepag, an ester thereof, or a salt thereof significantly dilates retinal blood vessels, and significantly increases blood flow. Therefore, omidenepag, an ester thereof, or a salt thereof is expected to protect retinal nerve cells and be useful for prevention and/or treatment of ophthalmic diseases involving retinal nerve cell disorder.Type: ApplicationFiled: September 27, 2018Publication date: June 18, 2020Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: TAKAZUMI TANIGUCHI, Takahiro AKAISHI, Hitoshi NAKAZAWA
-
Publication number: 20130210668Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B).Type: ApplicationFiled: March 26, 2013Publication date: August 15, 2013Inventors: Shigeru KINOSHITA, Kei Tashiro, Masakazu Nakano, Tomohito Yagi, Kazuhiko Mori, Yoko Ikeda, Takazumi Taniguchi, Masaaki Kageyama
-
Patent number: 8431345Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B).Type: GrantFiled: April 17, 2008Date of Patent: April 30, 2013Assignees: Santen Pharmaceutical Co., Ltd.Inventors: Shigeru Kinoshita, Kei Tashiro, Masakazu Nakano, Tomohito Yagi, Kazuhiko Mori, Yoko Ikeda, Takazumi Taniguchi, Masaaki Kageyama
-
Publication number: 20130012408Abstract: A method of determining the presence or the absence of a glaucoma risk by detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism, comparing the allele and/or the genotype detected with at least one of an allele and/or a genotype with a high-risk allele, wherein the presence of a glaucoma risk is determined in a case where the allele detected is the high-risk allele, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele or a heterozygote when the high-risk allele complies with a dominant genetic model, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele when the high-risk allele complies with a recessive genetic model.Type: ApplicationFiled: July 11, 2012Publication date: January 10, 2013Applicants: Shigeru Kinoshita, Santen Pharmaceutical Co., Ltd., Kei TashiroInventors: Shigeru KINOSHITA, Kei Tashiro, Masakazu Nakano, Tomohito Yagi, Kazuhiko Mori, Yoko Ikeda, Takazumi Taniguchi, Masaaki Kageyama
-
Publication number: 20110207122Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B).Type: ApplicationFiled: April 17, 2008Publication date: August 25, 2011Applicants: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Shigeru Kinoshita, Kei Tashiro, Masakazu Nakano, Tomohito Yagi, Kazuhiko Mori, Yoko Ikeda, Takazumi Taniguchi, Masaaki Kageyama
-
Publication number: 20100196895Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 514 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 514 (step B).Type: ApplicationFiled: April 17, 2008Publication date: August 5, 2010Applicants: SHIGERU KINOSHITA, KEI TASHIRO, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Shigeru Kinoshita, Kei Tashiro, Masakazu Nakano, Tomohito Yagi, Kazuhiko Mori, Yoko Ikeda, Takazumi Taniguchi, Masaaki Kageyama